Global Neuromuscular Blocking Drug Market Growth 2020-2025


Sep, 2020 | Report ID: 153499 | 137 | Pharmaceuticals and Healthcare

According to this study, over the next five years the Neuromuscular Blocking Drug market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Neuromuscular Blocking Drug business, shared in Chapter 3.

This report presents a comprehensive overview, market shares, and growth opportunities of Neuromuscular Blocking Drug market by product type, application, key manufacturers and key regions and countries.

This study specially analyses the impact of Covid-19 outbreak on the Neuromuscular Blocking Drug, covering the supply chain analysis, impact assessment to the Neuromuscular Blocking Drug market size growth rate in several scenarios, and the measures to be undertaken by Neuromuscular Blocking Drug companies in response to the COVID-19 epidemic.

Segmentation by type: breakdown data from 2015 to 2020, in Section 2.3; and forecast to 2025 in section 11.7.

Non-polarizing Agents

Depolarizing Agents

Segmentation by application: breakdown data from 2015 to 2020, in Section 2.4; and forecast to 2024 in section 11.8.

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

Others

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.

Hikma Pharmaceuticals

Merck

Bayer

Pfizer

Novartis

AbbVie

GSK

...

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives

To study and analyze the global Neuromuscular Blocking Drug consumption (value & volume) by key regions/countries, type and application, history data from 2015 to 2019, and forecast to 2025.

To understand the structure of Neuromuscular Blocking Drug market by identifying its various subsegments.

Focuses on the key global Neuromuscular Blocking Drug manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.

To analyze the Neuromuscular Blocking Drug with respect to individual growth trends, future prospects, and their contribution to the total market.

To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

To project the consumption of Neuromuscular Blocking Drug submarkets, with respect to key regions (along with their respective key countries).

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

To strategically profile the key players and comprehensively analyze their growth strategies.


Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

1 Scope of the Report

1.1 Market Introduction

1.2 Research Objectives

1.3 Years Considered

1.4 Market Research Methodology

1.5 Data Source

1.6 Economic Indicators

1.7 Currency Considered

2 Executive Summary

2.1 World Market Overview

2.1.1 Global Neuromuscular Blocking Drug Consumption 2015-2025

2.1.2 Neuromuscular Blocking Drug Consumption CAGR by Region

2.2 Neuromuscular Blocking Drug Segment by Type

2.2.1 Non-polarizing Agents

2.2.2 Depolarizing Agents

2.3 Neuromuscular Blocking Drug Consumption by Type

2.3.1 Global Neuromuscular Blocking Drug Consumption Market Share by Type (2015-2020)

2.3.2 Global Neuromuscular Blocking Drug Revenue and Market Share by Type (2015-2020)

2.3.3 Global Neuromuscular Blocking Drug Sale Price by Type (2015-2020)

2.4 Neuromuscular Blocking Drug Segment by Application

2.4.1 Hospital Pharmacy

2.4.2 Retail Pharmacy

2.4.3 Online Pharmacy

2.4.4 Others

2.5 Neuromuscular Blocking Drug Consumption by Application

2.5.1 Global Neuromuscular Blocking Drug Consumption Market Share by Type (2015-2020)

2.5.2 Global Neuromuscular Blocking Drug Value and Market Share by Type (2015-2020)

2.5.3 Global Neuromuscular Blocking Drug Sale Price by Type (2015-2020)

3 Global Neuromuscular Blocking Drug by Company

3.1 Global Neuromuscular Blocking Drug Sales Market Share by Company

3.1.1 Global Neuromuscular Blocking Drug Sales by Company (2018-2020)

3.1.2 Global Neuromuscular Blocking Drug Sales Market Share by Company (2018-2020)

3.2 Global Neuromuscular Blocking Drug Revenue Market Share by Company

3.2.1 Global Neuromuscular Blocking Drug Revenue by Company (2018-2020)

3.2.2 Global Neuromuscular Blocking Drug Revenue Market Share by Company (2018-2020)

3.3 Global Neuromuscular Blocking Drug Sale Price by Company

3.4 Global Neuromuscular Blocking Drug Manufacturing Base Distribution, Sales Area, Type by Company

3.4.1 Global Neuromuscular Blocking Drug Manufacturing Base Distribution and Sales Area by Company

3.4.2 Players Neuromuscular Blocking Drug Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2018-2020)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 Neuromuscular Blocking Drug by Regions

4.1 Neuromuscular Blocking Drug by Regions

4.2 Americas Neuromuscular Blocking Drug Consumption Growth

4.3 APAC Neuromuscular Blocking Drug Consumption Growth

4.4 Europe Neuromuscular Blocking Drug Consumption Growth

4.5 Middle East & Africa Neuromuscular Blocking Drug Consumption Growth

5 Americas

5.1 Americas Neuromuscular Blocking Drug Consumption by Countries

5.1.1 Americas Neuromuscular Blocking Drug Consumption by Countries (2015-2020)

5.1.2 Americas Neuromuscular Blocking Drug Value by Countries (2015-2020)

5.2 Americas Neuromuscular Blocking Drug Consumption by Type

5.3 Americas Neuromuscular Blocking Drug Consumption by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

5.8 Key Economic Indicators of Few Americas Countries

6 APAC

6.1 APAC Neuromuscular Blocking Drug Consumption by Regions

6.1.1 APAC Neuromuscular Blocking Drug Consumption by Regions (2015-2020)

6.1.2 APAC Neuromuscular Blocking Drug Value by Regions (2015-2020)

6.2 APAC Neuromuscular Blocking Drug Consumption by Type

6.3 APAC Neuromuscular Blocking Drug Consumption by Application

6.4 China

6.5 Japan

6.6 Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 Key Economic Indicators of Few APAC Regions

7 Europe

7.1 Europe Neuromuscular Blocking Drug by Countries

7.1.1 Europe Neuromuscular Blocking Drug Consumption by Countries (2015-2020)

7.1.2 Europe Neuromuscular Blocking Drug Value by Countries (2015-2020)

7.2 Europe Neuromuscular Blocking Drug Consumption by Type

7.3 Europe Neuromuscular Blocking Drug Consumption by Application

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

7.9 Key Economic Indicators of Few Europe Countries

8 Middle East & Africa

8.1 Middle East & Africa Neuromuscular Blocking Drug by Countries

8.1.1 Middle East & Africa Neuromuscular Blocking Drug Consumption by Countries (2015-2020)

8.1.2 Middle East & Africa Neuromuscular Blocking Drug Value by Countries (2015-2020)

8.2 Middle East & Africa Neuromuscular Blocking Drug Consumption by Type

8.3 Middle East & Africa Neuromuscular Blocking Drug Consumption by Application

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 Market Drivers, Challenges and Trends

9.1 Market Drivers and Impact

9.1.1 Growing Demand from Key Regions

9.1.2 Growing Demand from Key Applications and Potential Industries

9.2 Market Challenges and Impact

9.3 Market Trends

10 Marketing, Distributors and Customer

10.1 Sales Channel

10.1.1 Direct Channels

10.1.2 Indirect Channels

10.2 Neuromuscular Blocking Drug Distributors

10.3 Neuromuscular Blocking Drug Customer

11 Global Neuromuscular Blocking Drug Market Forecast

11.1 Global Neuromuscular Blocking Drug Consumption Forecast (2021-2025)

11.2 Global Neuromuscular Blocking Drug Forecast by Regions

11.2.1 Global Neuromuscular Blocking Drug Forecast by Regions (2021-2025)

11.2.2 Global Neuromuscular Blocking Drug Value Forecast by Regions (2021-2025)

11.2.3 Americas Consumption Forecast

11.2.4 APAC Consumption Forecast

11.2.5 Europe Consumption Forecast

11.2.6 Middle East & Africa Consumption Forecast

11.3 Americas Forecast by Countries

11.3.1 United States Market Forecast

11.3.2 Canada Market Forecast

11.3.3 Mexico Market Forecast

11.3.4 Brazil Market Forecast

11.4 APAC Forecast by Countries

11.4.1 China Market Forecast

11.4.2 Japan Market Forecast

11.4.3 Korea Market Forecast

11.4.4 Southeast Asia Market Forecast

11.4.5 India Market Forecast

11.4.6 Australia Market Forecast

11.5 Europe Forecast by Countries

11.5.1 Germany Market Forecast

11.5.2 France Market Forecast

11.5.3 UK Market Forecast

11.5.4 Italy Market Forecast

11.5.5 Russia Market Forecast

11.6 Middle East & Africa Forecast by Countries

11.6.1 Egypt Market Forecast

11.6.2 South Africa Market Forecast

11.6.3 Israel Market Forecast

11.6.4 Turkey Market Forecast

11.6.5 GCC Countries Market Forecast

11.7 Global Neuromuscular Blocking Drug Forecast by Type

11.8 Global Neuromuscular Blocking Drug Forecast by Application

12 Key Players Analysis

12.1 Hikma Pharmaceuticals

12.1.1 Company Information

12.1.2 Neuromuscular Blocking Drug Product Offered

12.1.3 Hikma Pharmaceuticals Neuromuscular Blocking Drug Sales, Revenue, Price and Gross Margin (2018-2020)

12.1.4 Main Business Overview

12.1.5 Hikma Pharmaceuticals Latest Developments

12.2 Merck

12.2.1 Company Information

12.2.2 Neuromuscular Blocking Drug Product Offered

12.2.3 Merck Neuromuscular Blocking Drug Sales, Revenue, Price and Gross Margin (2018-2020)

12.2.4 Main Business Overview

12.2.5 Merck Latest Developments

12.3 Bayer

12.3.1 Company Information

12.3.2 Neuromuscular Blocking Drug Product Offered

12.3.3 Bayer Neuromuscular Blocking Drug Sales, Revenue, Price and Gross Margin (2018-2020)

12.3.4 Main Business Overview

12.3.5 Bayer Latest Developments

12.4 Pfizer

12.4.1 Company Information

12.4.2 Neuromuscular Blocking Drug Product Offered

12.4.3 Pfizer Neuromuscular Blocking Drug Sales, Revenue, Price and Gross Margin (2018-2020)

12.4.4 Main Business Overview

12.4.5 Pfizer Latest Developments

12.5 Novartis

12.5.1 Company Information

12.5.2 Neuromuscular Blocking Drug Product Offered

12.5.3 Novartis Neuromuscular Blocking Drug Sales, Revenue, Price and Gross Margin (2018-2020)

12.5.4 Main Business Overview

12.5.5 Novartis Latest Developments

12.6 AbbVie

12.6.1 Company Information

12.6.2 Neuromuscular Blocking Drug Product Offered

12.6.3 AbbVie Neuromuscular Blocking Drug Sales, Revenue, Price and Gross Margin (2018-2020)

12.6.4 Main Business Overview

12.6.5 AbbVie Latest Developments

12.7 GSK

12.7.1 Company Information

12.7.2 Neuromuscular Blocking Drug Product Offered

12.7.3 GSK Neuromuscular Blocking Drug Sales, Revenue, Price and Gross Margin (2018-2020)

12.7.4 Main Business Overview

12.7.5 GSK Latest Developments

...

13 Research Findings and Conclusion

List of Tables

Table 1. Research Methodology

Table 2. Data Source

Table 3. Neuromuscular Blocking Drug Consumption CAGR by Region 2015-2025 ($ Millions)

Table 4. Major Players of Non-polarizing Agents

Table 5. Major Players of Depolarizing Agents

Table 6. Global Consumption Sales by Type (2015-2020)

Table 7. Global Neuromuscular Blocking Drug Consumption Market Share by Type (2015-2020)

Table 8. Global Neuromuscular Blocking Drug Revenue by Type (2015-2020) ($ million)

Table 9. Global Neuromuscular Blocking Drug Value Market Share by Type (2015-2020) ($ Millions)

Table 10. Global Neuromuscular Blocking Drug Sale Price by Type (2015-2020)

Table 11. Global Consumption Sales by Application (2015-2020)

Table 12. Global Neuromuscular Blocking Drug Consumption Market Share by Application (2015-2020)

Table 13. Global Neuromuscular Blocking Drug Value by Application (2015-2020)

Table 14. Global Neuromuscular Blocking Drug Value Market Share by Application (2015-2020)

Table 15. Global Neuromuscular Blocking Drug Sale Price by Application (2015-2020)

Table 16. Global Neuromuscular Blocking Drug Sales by Company (2017-2019) (K Units)

Table 17. Global Neuromuscular Blocking Drug Sales Market Share by Company (2017-2019)

Table 18. Global Neuromuscular Blocking Drug Revenue by Company (2017-2019) ($ Millions)

Table 19. Global Neuromuscular Blocking Drug Revenue Market Share by Company (2017-2019)

Table 20. Global Neuromuscular Blocking Drug Sale Price by Company (2017-2019)

Table 21. Global Neuromuscular Blocking Drug Manufacturing Base Distribution and Sales Area by Manufacturers

Table 22. Players Neuromuscular Blocking Drug Products Offered

Table 23. Neuromuscular Blocking Drug Concentration Ratio (CR3, CR5 and CR10) (2017-2019)

Table 24. Global Neuromuscular Blocking Drug Consumption by Regions 2015-2020 (K Units)

Table 25. Global Neuromuscular Blocking Drug Consumption Market Share by Regions 2015-2020

Table 26. Global Neuromuscular Blocking Drug Value by Regions 2015-2020 ($ Millions)

Table 27. Global Neuromuscular Blocking Drug Value Market Share by Regions 2015-2020

Table 28. Americas Neuromuscular Blocking Drug Consumption by Countries (2015-2020) (K Units)

Table 29. Americas Neuromuscular Blocking Drug Consumption Market Share by Countries (2015-2020)

Table 30. Americas Neuromuscular Blocking Drug Value by Countries (2015-2020) ($ Millions)

Table 31. Americas Neuromuscular Blocking Drug Value Market Share by Countries (2015-2020)

Table 32. Americas Neuromuscular Blocking Drug Consumption by Type (2015-2020) (K Units)

Table 33. Americas Neuromuscular Blocking Drug Consumption Market Share by Type (2015-2020)

Table 34. Americas Neuromuscular Blocking Drug Consumption by Application (2015-2020) (K Units)

Table 35. Americas Neuromuscular Blocking Drug Consumption Market Share by Application (2015-2020)

Table 36. APAC Neuromuscular Blocking Drug Consumption by Countries (2015-2020) (K Units)

Table 37. APAC Neuromuscular Blocking Drug Consumption Market Share by Countries (2015-2020)

Table 38. APAC Neuromuscular Blocking Drug Value by Regions (2015-2020) ($ Millions)

Table 39. APAC Neuromuscular Blocking Drug Value Market Share by Regions (2015-2020)

Table 40. APAC Neuromuscular Blocking Drug Consumption by Type (2015-2020) (K Units)

Table 41. APAC Neuromuscular Blocking Drug Consumption Market Share by Type (2015-2020)

Table 42. APAC Neuromuscular Blocking Drug Consumption by Application (2015-2020) (K Units)

Table 43. APAC Neuromuscular Blocking Drug Consumption Market Share by Application (2015-2020)

Table 44. Europe Neuromuscular Blocking Drug Consumption by Countries (2015-2020) (K Units)

Table 45. Europe Neuromuscular Blocking Drug Consumption Market Share by Countries (2015-2020)

Table 46. Europe Neuromuscular Blocking Drug Value by Countries (2015-2020) ($ Millions)

Table 47. Europe Neuromuscular Blocking Drug Value Market Share by Countries (2015-2020)

Table 48. Europe Neuromuscular Blocking Drug Consumption by Type (2015-2020) (K Units)

Table 49. Europe Neuromuscular Blocking Drug Consumption Market Share by Type (2015-2020)

Table 50. Europe Neuromuscular Blocking Drug Consumption by Application (2015-2020) (K Units)

Table 51. Europe Neuromuscular Blocking Drug Consumption Market Share by Application (2015-2020)

Table 52. Middle East & Africa Neuromuscular Blocking Drug Consumption by Countries (2015-2020) (K Units)

Table 53. Middle East & Africa Neuromuscular Blocking Drug Consumption Market Share by Countries (2015-2020)

Table 54. Middle East & Africa Neuromuscular Blocking Drug Value by Countries (2015-2020) ($ Millions)

Table 55. Middle East & Africa Neuromuscular Blocking Drug Value Market Share by Countries (2015-2020)

Table 56. Middle East & Africa Neuromuscular Blocking Drug Consumption by Type (2015-2020) (K Units)

Table 57. Middle East & Africa Neuromuscular Blocking Drug Consumption Market Share by Type (2015-2020)

Table 58. Middle East & Africa Neuromuscular Blocking Drug Consumption by Application (2015-2020) (K Units)

Table 59. Middle East & Africa Neuromuscular Blocking Drug Consumption Market Share by Application (2015-2020)

Table 60. Neuromuscular Blocking Drug Distributors List

Table 61. Neuromuscular Blocking Drug Customer List

Table 62. Global Neuromuscular Blocking Drug Consumption Forecast by Countries (2021-2025) (K Units)

Table 63. Global Neuromuscular Blocking Drug Consumption Market Forecast by Regions

Table 64. Global Neuromuscular Blocking Drug Value Forecast by Countries (2021-2025) ($ Millions)

Table 65. Global Neuromuscular Blocking Drug Value Market Share Forecast by Regions

Table 66. Global Neuromuscular Blocking Drug Consumption Forecast by Type (2021-2025) (K Units)

Table 67. Global Neuromuscular Blocking Drug Consumption Market Share Forecast by Type (2021-2025)

Table 68. Global Neuromuscular Blocking Drug Value Forecast by Type (2021-2025) ($ Millions)

Table 69. Global Neuromuscular Blocking Drug Value Market Share Forecast by Type (2021-2025)

Table 70. Global Neuromuscular Blocking Drug Consumption Forecast by Application (2021-2025) (K Units)

Table 71. Global Neuromuscular Blocking Drug Consumption Market Share Forecast by Application (2021-2025)

Table 72. Global Neuromuscular Blocking Drug Value Forecast by Application (2021-2025) ($ Millions)

Table 73. Global Neuromuscular Blocking Drug Value Market Share Forecast by Application (2021-2025)

Table 74. Hikma Pharmaceuticals Product Offered

Table 75. Hikma Pharmaceuticals Neuromuscular Blocking Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)

Table 76. Hikma Pharmaceuticals Main Business

Table 77. Hikma Pharmaceuticals Latest Developments

Table 78. Hikma Pharmaceuticals Basic Information, Company Total Revenue (in $ million), Neuromuscular Blocking Drug Manufacturing Base, Sales Area and Its Competitors

Table 79. Merck Product Offered

Table 80. Merck Neuromuscular Blocking Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)

Table 81. Merck Main Business

Table 82. Merck Latest Developments

Table 83. Merck Basic Information, Company Total Revenue (in $ million), Neuromuscular Blocking Drug Manufacturing Base, Sales Area and Its Competitors

Table 84. Bayer Product Offered

Table 85. Bayer Neuromuscular Blocking Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)

Table 86. Bayer Main Business

Table 87. Bayer Latest Developments

Table 88. Bayer Basic Information, Company Total Revenue (in $ million), Neuromuscular Blocking Drug Manufacturing Base, Sales Area and Its Competitors

Table 89. Pfizer Product Offered

Table 90. Pfizer Neuromuscular Blocking Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)

Table 91. Pfizer Main Business

Table 92. Pfizer Latest Developments

Table 93. Pfizer Basic Information, Company Total Revenue (in $ million), Neuromuscular Blocking Drug Manufacturing Base, Sales Area and Its Competitors

Table 94. Novartis Product Offered

Table 95. Novartis Neuromuscular Blocking Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)

Table 96. Novartis Main Business

Table 97. Novartis Latest Developments

Table 98. Novartis Basic Information, Company Total Revenue (in $ million), Neuromuscular Blocking Drug Manufacturing Base, Sales Area and Its Competitors

Table 99. AbbVie Product Offered

Table 100. AbbVie Neuromuscular Blocking Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)

Table 101. AbbVie Main Business

Table 102. AbbVie Latest Developments

Table 103. AbbVie Basic Information, Company Total Revenue (in $ million), Neuromuscular Blocking Drug Manufacturing Base, Sales Area and Its Competitors

Table 104. GSK Product Offered

Table 105. GSK Basic Information, Company Total Revenue (in $ million), Neuromuscular Blocking Drug Manufacturing Base, Sales Area and Its Competitors

Table 106. GSK Main Business

Table 107. GSK Latest Developments

Table 108. GSK Neuromuscular Blocking Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)

List of Figures

Figure 1. Picture of Neuromuscular Blocking Drug

Figure 2. Neuromuscular Blocking Drug Report Years Considered

Figure 3. Market Research Methodology

Figure 4. Global Neuromuscular Blocking Drug Consumption Growth Rate 2015-2025 (K Units)

Figure 5. Global Neuromuscular Blocking Drug Value Growth Rate 2015-2025 ($ Millions)

Figure 6. Product Picture of Non-polarizing Agents

Figure 7. Product Picture of Depolarizing Agents

Figure 8. Global Neuromuscular Blocking Drug Consumption Market Share by Type (2015-2020)

Figure 9. Global Neuromuscular Blocking Drug Value Market Share by Type (2015-2020)

Figure 10. Neuromuscular Blocking Drug Consumed in Hospital Pharmacy

Figure 11. Global Neuromuscular Blocking Drug Market: Hospital Pharmacy (2015-2020) (K Units)

Figure 12. Global Neuromuscular Blocking Drug Market: Hospital Pharmacy (2015-2020) ($ Millions)

Figure 13. Neuromuscular Blocking Drug Consumed in Retail Pharmacy

Figure 14. Global Neuromuscular Blocking Drug Market: Retail Pharmacy (2015-2020) (K Units)

Figure 15. Global Neuromuscular Blocking Drug Market: Retail Pharmacy (2015-2020) ($ Millions)

Figure 16. Neuromuscular Blocking Drug Consumed in Online Pharmacy

Figure 17. Global Neuromuscular Blocking Drug Market: Online Pharmacy (2015-2020) (K Units)

Figure 18. Global Neuromuscular Blocking Drug Market: Online Pharmacy (2015-2020) ($ Millions)

Figure 19. Neuromuscular Blocking Drug Consumed in Others

Figure 20. Global Neuromuscular Blocking Drug Market: Others (2015-2020) (K Units)

Figure 21. Global Neuromuscular Blocking Drug Market: Others (2015-2020) ($ Millions)

Figure 22. Global Neuromuscular Blocking Drug Consumption Market Share by Application (2015-2020)

Figure 23. Global Neuromuscular Blocking Drug Value Market Share by Application (2015-2020)

Figure 24. Global Neuromuscular Blocking Drug Sales Market Share by Company in 2017

Figure 25. Global Neuromuscular Blocking Drug Sales Market Share by Company in 2019

Figure 26. Global Neuromuscular Blocking Drug Revenue Market Share by Company in 2017

Figure 27. Global Neuromuscular Blocking Drug Revenue Market Share by Company in 2019

Figure 28. Global Neuromuscular Blocking Drug Sale Price by Company in 2019

Figure 29. Global Neuromuscular Blocking Drug Consumption Market Share by Regions 2015-2020

Figure 30. Global Neuromuscular Blocking Drug Value Market Share by Regions 2015-2020

Figure 31. Americas Neuromuscular Blocking Drug Consumption 2015-2020 (K Units)

Figure 32. Americas Neuromuscular Blocking Drug Value 2015-2020 ($ Millions)

Figure 33. APAC Neuromuscular Blocking Drug Consumption 2015-2020 (K Units)

Figure 34. APAC Neuromuscular Blocking Drug Value 2015-2020 ($ Millions)

Figure 35. Europe Neuromuscular Blocking Drug Consumption 2015-2020 (K Units)

Figure 36. Europe Neuromuscular Blocking Drug Value 2015-2020 ($ Millions)

Figure 37. Middle East & Africa Neuromuscular Blocking Drug Consumption 2015-2020 (K Units)

Figure 38. Middle East & Africa Neuromuscular Blocking Drug Value 2015-2020 ($ Millions)

Figure 39. Americas Neuromuscular Blocking Drug Consumption Market Share by Countries in 2019

Figure 40. Americas Neuromuscular Blocking Drug Value Market Share by Countries in 2019

Figure 41. Americas Neuromuscular Blocking Drug Consumption Market Share by Type in 2019

Figure 42. Americas Neuromuscular Blocking Drug Consumption Market Share by Application in 2019

Figure 43. United States Neuromuscular Blocking Drug Consumption Growth 2015-2020 (K Units)

Figure 44. United States Neuromuscular Blocking Drug Value Growth 2015-2020 ($ Millions)

Figure 45. Canada Neuromuscular Blocking Drug Consumption Growth 2015-2020 (K Units)

Figure 46. Canada Neuromuscular Blocking Drug Value Growth 2015-2020 ($ Millions)

Figure 47. Mexico Neuromuscular Blocking Drug Consumption Growth 2015-2020 (K Units)

Figure 48. Mexico Neuromuscular Blocking Drug Value Growth 2015-2020 ($ Millions)

Figure 49. APAC Neuromuscular Blocking Drug Consumption Market Share by Countries in 2019

Figure 50. APAC Neuromuscular Blocking Drug Value Market Share by Regions in 2019

Figure 51. APAC Neuromuscular Blocking Drug Consumption Market Share by Type in 2019

Figure 52. APAC Neuromuscular Blocking Drug Consumption Market Share by Application in 2019

Figure 53. China Neuromuscular Blocking Drug Consumption Growth 2015-2020 (K Units)

Figure 54. China Neuromuscular Blocking Drug Value Growth 2015-2020 ($ Millions)

Figure 55. Japan Neuromuscular Blocking Drug Consumption Growth 2015-2020 (K Units)

Figure 56. Japan Neuromuscular Blocking Drug Value Growth 2015-2020 ($ Millions)

Figure 57. Korea Neuromuscular Blocking Drug Consumption Growth 2015-2020 (K Units)

Figure 58. Korea Neuromuscular Blocking Drug Value Growth 2015-2020 ($ Millions)

Figure 59. Southeast Asia Neuromuscular Blocking Drug Consumption Growth 2015-2020 (K Units)

Figure 60. Southeast Asia Neuromuscular Blocking Drug Value Growth 2015-2020 ($ Millions)

Figure 61. India Neuromuscular Blocking Drug Consumption Growth 2015-2020 (K Units)

Figure 62. India Neuromuscular Blocking Drug Value Growth 2015-2020 ($ Millions)

Figure 63. Australia Neuromuscular Blocking Drug Consumption Growth 2015-2020 (K Units)

Figure 64. Australia Neuromuscular Blocking Drug Value Growth 2015-2020 ($ Millions)

Figure 65. Europe Neuromuscular Blocking Drug Consumption Market Share by Countries in 2019

Figure 66. Europe Neuromuscular Blocking Drug Value Market Share by Countries in 2019

Figure 67. Europe Neuromuscular Blocking Drug Consumption Market Share by Type in 2019

Figure 68. Europe Neuromuscular Blocking Drug Consumption Market Share by Application in 2019

Figure 69. Germany Neuromuscular Blocking Drug Consumption Growth 2015-2020 (K Units)

Figure 70. Germany Neuromuscular Blocking Drug Value Growth 2015-2020 ($ Millions)

Figure 71. France Neuromuscular Blocking Drug Consumption Growth 2015-2020 (K Units)

Figure 72. France Neuromuscular Blocking Drug Value Growth 2015-2020 ($ Millions)

Figure 73. UK Neuromuscular Blocking Drug Consumption Growth 2015-2020 (K Units)

Figure 74. UK Neuromuscular Blocking Drug Value Growth 2015-2020 ($ Millions)

Figure 75. Italy Neuromuscular Blocking Drug Consumption Growth 2015-2020 (K Units)

Figure 76. Italy Neuromuscular Blocking Drug Value Growth 2015-2020 ($ Millions)

Figure 77. Russia Neuromuscular Blocking Drug Consumption Growth 2015-2020 (K Units)

Figure 78. Russia Neuromuscular Blocking Drug Value Growth 2015-2020 ($ Millions)

Figure 79. Middle East & Africa Neuromuscular Blocking Drug Consumption Market Share by Countries in 2019

Figure 80. Middle East & Africa Neuromuscular Blocking Drug Value Market Share by Countries in 2019

Figure 81. Middle East & Africa Neuromuscular Blocking Drug Consumption Market Share by Type in 2019

Figure 82. Middle East & Africa Neuromuscular Blocking Drug Consumption Market Share by Application in 2019

Figure 83. Egypt Neuromuscular Blocking Drug Consumption Growth 2015-2020 (K Units)

Figure 84. Egypt Neuromuscular Blocking Drug Value Growth 2015-2020 ($ Millions)

Figure 85. South Africa Neuromuscular Blocking Drug Consumption Growth 2015-2020 (K Units)

Figure 86. South Africa Neuromuscular Blocking Drug Value Growth 2015-2020 ($ Millions)

Figure 87. Israel Neuromuscular Blocking Drug Consumption Growth 2015-2020 (K Units)

Figure 88. Israel Neuromuscular Blocking Drug Value Growth 2015-2020 ($ Millions)

Figure 89. Turkey Neuromuscular Blocking Drug Consumption Growth 2015-2020 (K Units)

Figure 90. Turkey Neuromuscular Blocking Drug Value Growth 2015-2020 ($ Millions)

Figure 91. GCC Countries Neuromuscular Blocking Drug Consumption Growth 2015-2020 (K Units)

Figure 92. GCC Countries Neuromuscular Blocking Drug Value Growth 2015-2020 ($ Millions)

Figure 93. Global Neuromuscular Blocking Drug Consumption Growth Rate Forecast (2021-2025) (K Units)

Figure 94. Global Neuromuscular Blocking Drug Value Growth Rate Forecast (2021-2025) ($ Millions)

Figure 95. Americas Neuromuscular Blocking Drug Consumption 2021-2025 (K Units)

Figure 96. Americas Neuromuscular Blocking Drug Value 2021-2025 ($ Millions)

Figure 97. APAC Neuromuscular Blocking Drug Consumption 2021-2025 (K Units)

Figure 98. APAC Neuromuscular Blocking Drug Value 2021-2025 ($ Millions)

Figure 99. Europe Neuromuscular Blocking Drug Consumption 2021-2025 (K Units)

Figure 100. Europe Neuromuscular Blocking Drug Value 2021-2025 ($ Millions)

Figure 101. Middle East & Africa Neuromuscular Blocking Drug Consumption 2021-2025 (K Units)

Figure 102. Middle East & Africa Neuromuscular Blocking Drug Value 2021-2025 ($ Millions)

Figure 103. United States Neuromuscular Blocking Drug Consumption 2021-2025 (K Units)

Figure 104. United States Neuromuscular Blocking Drug Value 2021-2025 ($ Millions)

Figure 105. Canada Neuromuscular Blocking Drug Consumption 2021-2025 (K Units)

Figure 106. Canada Neuromuscular Blocking Drug Value 2021-2025 ($ Millions)

Figure 107. Mexico Neuromuscular Blocking Drug Consumption 2021-2025 (K Units)

Figure 108. Mexico Neuromuscular Blocking Drug Value 2021-2025 ($ Millions)

Figure 109. Brazil Neuromuscular Blocking Drug Consumption 2021-2025 (K Units)

Figure 110. Brazil Neuromuscular Blocking Drug Value 2021-2025 ($ Millions)

Figure 111. China Neuromuscular Blocking Drug Consumption 2021-2025 (K Units)

Figure 112. China Neuromuscular Blocking Drug Value 2021-2025 ($ Millions)

Figure 113. Japan Neuromuscular Blocking Drug Consumption 2021-2025 (K Units)

Figure 114. Japan Neuromuscular Blocking Drug Value 2021-2025 ($ Millions)

Figure 115. Korea Neuromuscular Blocking Drug Consumption 2021-2025 (K Units)

Figure 116. Korea Neuromuscular Blocking Drug Value 2021-2025 ($ Millions)

Figure 117. Southeast Asia Neuromuscular Blocking Drug Consumption 2021-2025 (K Units)

Figure 118. Southeast Asia Neuromuscular Blocking Drug Value 2021-2025 ($ Millions)

Figure 119. India Neuromuscular Blocking Drug Consumption 2021-2025 (K Units)

Figure 120. India Neuromuscular Blocking Drug Value 2021-2025 ($ Millions)

Figure 121. Australia Neuromuscular Blocking Drug Consumption 2021-2025 (K Units)

Figure 122. Australia Neuromuscular Blocking Drug Value 2021-2025 ($ Millions)

Figure 123. Germany Neuromuscular Blocking Drug Consumption 2021-2025 (K Units)

Figure 124. Germany Neuromuscular Blocking Drug Value 2021-2025 ($ Millions)

Figure 125. France Neuromuscular Blocking Drug Consumption 2021-2025 (K Units)

Figure 126. France Neuromuscular Blocking Drug Value 2021-2025 ($ Millions)

Figure 127. UK Neuromuscular Blocking Drug Consumption 2021-2025 (K Units)

Figure 128. UK Neuromuscular Blocking Drug Value 2021-2025 ($ Millions)

Figure 129. Italy Neuromuscular Blocking Drug Consumption 2021-2025 (K Units)

Figure 130. Italy Neuromuscular Blocking Drug Value 2021-2025 ($ Millions)

Figure 131. Russia Neuromuscular Blocking Drug Consumption 2021-2025 (K Units)

Figure 132. Russia Neuromuscular Blocking Drug Value 2021-2025 ($ Millions)

Figure 133. Spain Neuromuscular Blocking Drug Consumption 2021-2025 (K Units)

Figure 134. Spain Neuromuscular Blocking Drug Value 2021-2025 ($ Millions)

Figure 135. Egypt Neuromuscular Blocking Drug Consumption 2021-2025 (K Units)

Figure 136. Egypt Neuromuscular Blocking Drug Value 2021-2025 ($ Millions)

Figure 137. South Africa Neuromuscular Blocking Drug Consumption 2021-2025 (K Units)

Figure 138. South Africa Neuromuscular Blocking Drug Value 2021-2025 ($ Millions)

Figure 139. Israel Neuromuscular Blocking Drug Consumption 2021-2025 (K Units)

Figure 140. Israel Neuromuscular Blocking Drug Value 2021-2025 ($ Millions)

Figure 141. Turkey Neuromuscular Blocking Drug Consumption 2021-2025 (K Units)

Figure 142. Turkey Neuromuscular Blocking Drug Value 2021-2025 ($ Millions)

Figure 143. GCC Countries Neuromuscular Blocking Drug Consumption 2021-2025 (K Units)

Figure 144. GCC Countries Neuromuscular Blocking Drug Value 2021-2025 ($ Millions)

Figure 145. Hikma Pharmaceuticals Neuromuscular Blocking Drug Market Share (2018-2020)

Figure 146. Merck Neuromuscular Blocking Drug Market Share (2018-2020)

Figure 147. Bayer Neuromuscular Blocking Drug Market Share (2018-2020)

Figure 148. Pfizer Neuromuscular Blocking Drug Market Share (2018-2020)

Figure 149. Novartis Neuromuscular Blocking Drug Market Share (2018-2020)

Figure 150. AbbVie Neuromuscular Blocking Drug Market Share (2018-2020)

Figure 151. GSK Neuromuscular Blocking Drug Market Share (2018-2020)

Sample Request is not available